sellWeak cluster of 610b5-1 plan
Andrew Cheng sold $802k of AKRO
President and CEO at Akero Therapeutics, Inc.. 25,000 shares at an average of $32.09, traded Dec 2, 2024, filed Dec 4, 2024.
Warning score
27Value
$802k
25,000 shares
Holdings after
605,417
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +22Trade size$802k at market
- 0Share of holdings soldSold 4.0% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-133435, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 2, 2024 | MOption exercise Common Stock10b5-1 | +25,000 | $21.10 | $528k | 630,417 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock10b5-1 | -25,000 | $32.09 | $802k | 605,417 | Dec 4, 2024 |
| Dec 2, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 111,029 | Dec 4, 2024 |
Related signals
Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 51Moderate | buy | AKRO Akero Therapeutics, Inc. | G. Walmsley Graham director | $8.8M | 200,000 | |
| 12Weak | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $448k | 10,000 | |
| 30Weak | sell 6 | AKRO Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $23k | 516 | |
| 42Moderate | sell 6 | AKRO Akero Therapeutics, Inc. | William Richard White Chief Financial Officer | $30k | 676 | |
| 35Weak | sell 6 | AKRO Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $28k | 614 | |
| 40Moderate | sell 6 | AKRO Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $27k | 607 | |
| 49Moderate | sell 6 | AKRO Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $78k | 1,738 | |
| 45Moderate | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $1.3M | 30,000 | |
| 14Weak | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $557k | 12,500 | |
| 2Weak | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | Patrick Lamy Senior VP, Commercial Strategy | $48k | 1,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.